New drug combo offers hope for tough pancreatic cancer
NCT ID NCT04820179
First seen Dec 10, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study tests a combination of two drugs, atezolizumab and cabozantinib, in 30 people with advanced pancreatic cancer that has spread and stopped responding to standard treatments. The goal is to see if the combo can shrink tumors or slow the disease. Researchers will also check for side effects and study how the drugs affect the immune system.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Arizona Cancer Center
Tucson, Arizona, 85724, United States
Conditions
Explore the condition pages connected to this study.